Your browser doesn't support javascript.
loading
Mostrar: 20 | 50 | 100
Resultados 1 - 2 de 2
Filtrar
Mais filtros










Base de dados
Intervalo de ano de publicação
1.
Cancer Res ; 60(13): 3569-76, 2000 Jul 01.
Artigo em Inglês | MEDLINE | ID: mdl-10910070

RESUMO

HER-2/neu (neu-N) transgenic mice, which express the nontransforming rat proto-oncogene, develop spontaneous focal mammary adenocarcinomas beginning at 5-6 months of age. The development and histology of these tumors bears a striking resemblance to what is seen in patients with breast cancer. We have characterized the immunological responses to HER-2/neu (neu) in this animal model. neu-positive tumor lines, which were derived from spontaneous tumors that formed in neu-N animals, are highly immunogenic in parental, FVB/N mice. In contrast, a 100-fold lower tumor challenge is sufficient for growth in 100% of transgenic animals. Despite significant tolerance to the transgene, neu-specific immune responses similar to those observed in breast cancer patients can be demonstrated in neu-N mice prior to vaccination. Both cellular and humoral neu-specific responses in transgenic mice can be boosted with neu-specific vaccination, although to a significantly lesser degree than what is observed in FVB/N mice, indicating that the T cells involved are less responsive than in the nontoleragenic parental strain. Using irradiated whole-cell and recombinant vaccinia virus vaccinations we are able to protect neu-N mice from a neu-expressing tumor challenge. T-cell depletion experiments demonstrated that the observed protection is T cell dependent. The vaccine-dependent neu-specific immune response is also sufficient to delay the onset of spontaneous tumor formation in these mice. These data suggest that, despite tolerance to neu in this transgenic model, it is possible to immunize neu-specific T cells to achieve neu-specific tumor rejection in vivo. These transgenic mice provide a spontaneous tumor model for identifying vaccine approaches potent enough to overcome mechanisms of immune tolerance that are likely to exist in patients with cancer.


Assuntos
Adenocarcinoma/genética , Adenocarcinoma/imunologia , Vacinas Anticâncer , Neoplasias Mamárias Experimentais/genética , Neoplasias Mamárias Experimentais/imunologia , Receptor ErbB-2/imunologia , Linfócitos T/imunologia , Células 3T3 , Adenocarcinoma/terapia , Animais , Feminino , Genes erbB-2 , Tolerância Imunológica , Neoplasias Mamárias Experimentais/terapia , Camundongos , Camundongos Endogâmicos , Camundongos Transgênicos , Ratos , Receptor ErbB-2/genética , Reação em Cadeia da Polimerase Via Transcriptase Reversa , Timo/imunologia
2.
Equine Vet J ; 16(3): 207-9, 1984 May.
Artigo em Inglês | MEDLINE | ID: mdl-6734587

RESUMO

Total and differential leucocyte counts have been determined by electronic counting techniques in 474, two-to-four-year-old healthy Thoroughbreds in training. The ranges of values observed (particular those for neutrophils and lymphocytes) were narrower than previously described. Absolute and percentage lymphocyte values were significantly decreased with advancing age causing a relative increase in percentage neutrophils. The fall in absolute lymphocyte numbers was the main cause for a significant decrease in total leucocytes with age. Frequency plots for each variable showed that, with the exception of the eosinophil count, data from other leucocyte cell types following either a normal or lognormal distribution.


Assuntos
Cavalos/sangue , Leucócitos/citologia , Corrida , Envelhecimento , Animais , Eosinófilos/citologia , Contagem de Leucócitos/veterinária , Linfócitos/citologia , Monócitos/citologia , Neutrófilos/citologia
SELEÇÃO DE REFERÊNCIAS
DETALHE DA PESQUISA
...